MMG-11 quarterhydrate

Name: MMG-11 quarterhydrate
Brand: MedChemExpress
SKU: HY-112146A
Rating: 5.0 (5 reviews)

Cat. No.: HY-112146A Purity: 98.74%: Data Sheet
COA

SDS
Handling Instructions
FAQs
Technical Support

MMG-11 quarterhydrate is a potent and selective human TLR2 antagonist with low cytotoxicity. MMG-11 quarterhydrate inhibits both TLR2/1 and TLR2/6 signaling with IC₅₀s of 1.7 μM for Pam₃CSK₄-induced hTLR2/1 and 5.7 μM for Pam₂CSK₄-induced hTLR2/6 responses.

For research use only. We do not sell to patients.

Size	Stock	Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	In-stock	Estimated Time of Arrival: December 31
Solid
5 mg	In-stock	Estimated Time of Arrival: December 31
10 mg	In-stock	Estimated Time of Arrival: December 31
25 mg	In-stock	Estimated Time of Arrival: December 31
50 mg	In-stock	Estimated Time of Arrival: December 31
100 mg	Get quote
200 mg	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 5 publication(s) in Google Scholar

Other Forms of MMG-11 quarterhydrate:

MMG-11 In-stock

5 Publications Citing Use of MCE MMG-11 quarterhydrate

Cell Proliferation/Viability Assay

RT-PCR

Flow Cytometry

Cell Imaging/Staining

: MMG-11 quarterhydrate purchased from MedChemExpress. Usage Cited in: Biomed Pharmacother. 2025 Sep 17:192:118569. [Abstract]; APAP-induced NETs formation through TLR2/NLRP3/GSDMD signaling. Sytox green-based NETosis assay and ATP-based cell viability. TLR2i (MMG-11, HY-112146).

: MMG-11 quarterhydrate purchased from MedChemExpress. Usage Cited in: Adv Biol (Weinh). 2025 Jun 4:e00761. [Abstract]; The MET formation of macrophages pretreated with inhibitors of TLR2 (HY‐112146; MMG-11), TLR4 (HY‐11109; Resatorvid) and RAGE (HY‐P2268; RAGE antagonist peptide) prior to incubation with pyroptotic‐CM was evaluated with SYTOX Green staining and detected by flow cytometry.

: MMG-11 quarterhydrate purchased from MedChemExpress. Usage Cited in: Adv Biol (Weinh). 2025 Jun 4:e00761. [Abstract]; Macrophages were pretreated with inhibitors of TLR2 (MMG-11; HY‐112146), TLR4 (Resatorvid; HY‐11109), TLR9 (TLR7/8/9-IN-1; HY-131952) and RAGE (RAGE antagonist peptide; HY‐P2268) prior to coculture with pyroptotic‐CM, and the p‐p38 and p‐p65 levels in macrophages were measured by western blotting.

: MMG-11 quarterhydrate purchased from MedChemExpress. Usage Cited in: Adv Biol (Weinh). 2025 Jun 4:e00761. [Abstract]; The MET formation of macrophages pretreated with inhibitors of (MMG-11; HY‐112146), TLR4 (Resatorvid; HY‐11109) and RAGE (RAGE antagonist peptide; HY‐P2268) prior to incubation with pyroptotic‐CM was detected by flow cytometry.

: MMG-11 quarterhydrate purchased from MedChemExpress. Usage Cited in: Cell Commun Signal. 2023 May 1;21(1):86. [Abstract]; Neutrophils isolated from healthy individuals were pretreated with inhibitors of TLR2 (HY-112146; MMG-11), TLR4 (HY-107575; TLR4-IN-C34 ), TLR9 (HY-131952; TLR7/8/9-IN-1) and RAGE (HY-P2268; RAGE antagonist peptide) for 1 h prior to coculture with hypoxic-CM from GC cells, and the p-p38 level in neutrophils was measured by western blotting.

: MMG-11 quarterhydrate purchased from MedChemExpress. Usage Cited in: Cell Commun Signal. 2023 May 1;21(1):86. [Abstract]; Neutrophils isolated from healthy individuals were pretreated with inhibitors of TLR2 (HY-112146; MMG-11), TLR4 (HY-107575; TLR4-IN-C34 ), TLR9 (HY-131952; TLR7/8/9-IN-1) and RAGE (HY-P2268; RAGE antagonist peptide) for 1 h prior to coculture with hypoxic-CM from GC cells, and the NET formation was detected with MPO and citH3 staining. Magnification: 20 × . Scale bars: 50 μm. All values are the means ± SDs. ns = not significant, **P < 0.01

: MMG-11 quarterhydrate purchased from MedChemExpress. Usage Cited in: Mol Immunol. 2021 Feb;130:85-95. [Abstract]; RAW264.7 cells were treated with Pam3CSK4 BCG or MMG-11 for 12 h respectively. The expression of LincRNA-Cox2 was detected by qRT-PCR.

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All Toll-like Receptor (TLR) Isoform Specific Products:

View All Isoforms

TLR3 TLR8 TLR9 TLR2 TLR4 TLR7 TLR1 TLR6

Biological Activity
Purity & Documentation
References
Customer Review

Description

IC₅₀ & Target^[1]

TLR2

In Vitro

MMG-11 neither shows cellular toxicity nor interference with signaling induced by other TLR agonists, IL-1β or TNF. MMG-11 (0.01-100 μM) shows no cytotoxic effects up to 100 μM in peripheral blood mononuclear cells (PBMCs)^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Cytotoxicity Assay^[1]

Cell Line:	PBMCs
Concentration:	0.01, 1, 10, 100 µM
Incubation Time:
Result:	Showed no cytotoxic effects up to 100 µM.

Molecular Weight

310.78

Formula

C₁₅H₁₄O₇.1/4H₂O

Appearance

Solid

Color

Off-white to light yellow

SMILES

OC1=C(O)C(O)=C(C(CC2=CC=C(C(OCC)=O)O2)=O)C=C1.[1/4].O

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL (321.77 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	3.2177 mL	16.0886 mL	32.1771 mL
5 mM	0.6435 mL	3.2177 mL	6.4354 mL
10 mM	0.3218 mL	1.6089 mL	3.2177 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (8.04 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 2

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (8.04 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.
Protocol 3

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (6.69 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 98.74%

Select Batch:

Data Sheet (275 KB) SDS (251 KB)

COA (250 KB) LCMS (98 KB) Elemental Analysis Report (108 KB)

Handling Instructions (2659 KB)

References

[1]. Grabowski M, et al. Identification of a pyrogallol derivative as a potent and selective human TLR2 antagonist by structure-based virtual screening. Biochem Pharmacol. 2018 Aug;154:148-160. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	3.2177 mL	16.0886 mL	32.1771 mL	80.4428 mL
	5 mM	0.6435 mL	3.2177 mL	6.4354 mL	16.0886 mL
	10 mM	0.3218 mL	1.6089 mL	3.2177 mL	8.0443 mL
	15 mM	0.2145 mL	1.0726 mL	2.1451 mL	5.3629 mL
	20 mM	0.1609 mL	0.8044 mL	1.6089 mL	4.0221 mL
	25 mM	0.1287 mL	0.6435 mL	1.2871 mL	3.2177 mL
	30 mM	0.1073 mL	0.5363 mL	1.0726 mL	2.6814 mL
	40 mM	0.0804 mL	0.4022 mL	0.8044 mL	2.0111 mL
	50 mM	0.0644 mL	0.3218 mL	0.6435 mL	1.6089 mL
	60 mM	0.0536 mL	0.2681 mL	0.5363 mL	1.3407 mL
	80 mM	0.0402 mL	0.2011 mL	0.4022 mL	1.0055 mL
	100 mM	0.0322 mL	0.1609 mL	0.3218 mL	0.8044 mL